INVION LIMITED — Board/Management Information 2011

Dec 27, 2011

==> picture [595 x 108] intentionally omitted <==

27 December 2011

The Manager Company Announcements Office ASX Limited 20 Bridge St SYDNEY NSW 2000

Dear Sir,

RESIGNATIONS FROM THE BOARD OF DIRECTORS

BRISBANE: Australian early-stage drug development company CBio Limited (ASX:CBZ) today announced the resignations of non-executive directors Dr Terje Kalland and Dr Thomas Lonngren from the Board.

Dr Kalland, MD, Ph.D, is the Chief Scientific Officer of Karolinska Development in Stockholm, Sweden. He is a former professor of tumour immunology and has served 23 years in the pharmaceutical industry. He was senior vice president of the Biopharmaceuticals Research Unit at Novo Nordisk 2005-2011, and his main expertise is in discovery research, preclinical development and phase I / II clinical development with focus on oncology and autoimmune diseases. Dr Kalland was appointed to the Board of CBio in 2010.

Dr Thomas Lönngren acts as Independent Strategy Advisor through his company Pharma Executive Consulting. He served as the Executive Director of the European Medicines Agency until December 2010, and formerly served as Deputy Director-General of the Swedish Medical Products Agency. Dr Lönngren was an Honorary Member of the Royal Pharmaceutical Society of Great Britain in 2003, was made an Honorary Fellow of the Royal College of Physicians in 2004, and received Drug Information Associations Distinguished Career Award in 2008. Dr Lonngren was appointed to the Board of CBio in 2011.

“I am joined by the Board and the staff of CBio in thanking Dr Kalland and Dr Lonngren for their contribution to the development of XToll and for their service to the Board,” said CBio Chairman, Dr Ralph Craven.

For and on behalf of the Board of CBio Limited

ROSLYNN SHAND

Company Secretary

---

Enquiries

Melanie Farris, Communications and Corporate Affairs Manager, CBio Limited T: +61 (0)449 148 448 E: melanie.farris@cbio.com.au